. | Abnormal Riata . | Normal Riata . | P . |
---|---|---|---|
N = 69 . | N = 215 . | ||
Age, years | 66 ± 11 | 68 ± 10 | 0.05 |
Mean time since implantation, years | 6.7 ± 1.2 | 5.9 ± 1.4 | <0.001 |
Venous access, % | |||
Subclavian | 35 | 29 | 0.45 |
Cephalic | 65 | 71 | |
DFT testinga, mean energy, J | 15 ± 6 | 16 ± 5 | 0.18 |
Male sex, % | 80 | 78 | 0.74 |
BMI, kg/m2 | 27 ± 5 | 28 ± 4 | 0.58 |
LVEF, % | 32 ± 13 | 31 ± 13 | 0.56 |
CAD, % | 70 | 71 | 0.88 |
Diabetes mellitus, % | 25 | 27 | 0.76 |
ICD indication, % | |||
Primary prevention | 58 | 61 | |
Secondary prevention | 42 | 39 | 0.67 |
. | Abnormal Riata . | Normal Riata . | P . |
---|---|---|---|
N = 69 . | N = 215 . | ||
Age, years | 66 ± 11 | 68 ± 10 | 0.05 |
Mean time since implantation, years | 6.7 ± 1.2 | 5.9 ± 1.4 | <0.001 |
Venous access, % | |||
Subclavian | 35 | 29 | 0.45 |
Cephalic | 65 | 71 | |
DFT testinga, mean energy, J | 15 ± 6 | 16 ± 5 | 0.18 |
Male sex, % | 80 | 78 | 0.74 |
BMI, kg/m2 | 27 ± 5 | 28 ± 4 | 0.58 |
LVEF, % | 32 ± 13 | 31 ± 13 | 0.56 |
CAD, % | 70 | 71 | 0.88 |
Diabetes mellitus, % | 25 | 27 | 0.76 |
ICD indication, % | |||
Primary prevention | 58 | 61 | |
Secondary prevention | 42 | 39 | 0.67 |
Data are expressed as mean ± SD.
P < 0.05 indicates statistical significance.
BMI, body mass index; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; NS, non-significant.
aDFT = defibrillation threshold, instead of a real DFT a safety margin testing was performed with a safety margin of ≥10 J.
. | Abnormal Riata . | Normal Riata . | P . |
---|---|---|---|
N = 69 . | N = 215 . | ||
Age, years | 66 ± 11 | 68 ± 10 | 0.05 |
Mean time since implantation, years | 6.7 ± 1.2 | 5.9 ± 1.4 | <0.001 |
Venous access, % | |||
Subclavian | 35 | 29 | 0.45 |
Cephalic | 65 | 71 | |
DFT testinga, mean energy, J | 15 ± 6 | 16 ± 5 | 0.18 |
Male sex, % | 80 | 78 | 0.74 |
BMI, kg/m2 | 27 ± 5 | 28 ± 4 | 0.58 |
LVEF, % | 32 ± 13 | 31 ± 13 | 0.56 |
CAD, % | 70 | 71 | 0.88 |
Diabetes mellitus, % | 25 | 27 | 0.76 |
ICD indication, % | |||
Primary prevention | 58 | 61 | |
Secondary prevention | 42 | 39 | 0.67 |
. | Abnormal Riata . | Normal Riata . | P . |
---|---|---|---|
N = 69 . | N = 215 . | ||
Age, years | 66 ± 11 | 68 ± 10 | 0.05 |
Mean time since implantation, years | 6.7 ± 1.2 | 5.9 ± 1.4 | <0.001 |
Venous access, % | |||
Subclavian | 35 | 29 | 0.45 |
Cephalic | 65 | 71 | |
DFT testinga, mean energy, J | 15 ± 6 | 16 ± 5 | 0.18 |
Male sex, % | 80 | 78 | 0.74 |
BMI, kg/m2 | 27 ± 5 | 28 ± 4 | 0.58 |
LVEF, % | 32 ± 13 | 31 ± 13 | 0.56 |
CAD, % | 70 | 71 | 0.88 |
Diabetes mellitus, % | 25 | 27 | 0.76 |
ICD indication, % | |||
Primary prevention | 58 | 61 | |
Secondary prevention | 42 | 39 | 0.67 |
Data are expressed as mean ± SD.
P < 0.05 indicates statistical significance.
BMI, body mass index; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; NS, non-significant.
aDFT = defibrillation threshold, instead of a real DFT a safety margin testing was performed with a safety margin of ≥10 J.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.